Esorubicin cardiotoxicity in vitro: antagonism by pimobendan.
Galatulas
I
I
Dipartimento di Farmacologia dell'Universita, Milano, Italia.
Bossa
R
R
Efstathiu
G
G
Ninci
M A
MA
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors / Q000633:toxicity*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000633:toxicity; D004558:Electric Stimulation; D006168:Guinea Pigs; D006321:Heart / Q000502:physiology; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D066298:In Vitro Techniques; D011724:Pyridazines / Q000494:pharmacology*
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D011724:Pyridazines; C041648:pimobendan; D004317:Doxorubicin; C030851:esorubicin